U.s. fda approves takeda's takhzyro® (lanadelumab-flyo) to prevent hereditary angioedema (hae) attacks in children 2 years of age and older

Osaka, japan & cambridge, mass.--( business wire )--takeda ( tse:4502/nyse:tak ) today announced that the u.s. food and drug administration (fda) has approved the supplemental biologics license application (sbla) for the expanded use of takhzyro® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (hae) in pediatric patients 2 to
TAK Ratings Summary
TAK Quant Ranking